BioAgilytix announces appointment of Dr. Linda Robbie as Chief Operating Officer

August 16, 2022

Durham, NC, August 17, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading contract research organization supporting pharmaceutical and biotech partners in all phases of drug development, has announced the appointment of Dr. Linda Robbie as Chief Operating Officer. This appointment was effective as of August 9th, 2022.


For the past three years, Dr. Robbie has served as Vice President and General Manager of

Boston operations, responsible for leading all Bioanalytical Services at BioAgilytix’s Boston, MA

Laboratory. During this time, she directed all initiatives relating to science, technology, and

laboratory operations.


Dr. Robbie has more than 25 years of experience with biomarker assay technologies, including

20 years of experience in scientific leadership positions. She was previously Senior Vice

President of Science and Laboratory Operations at Cambridge Biomedical and joined

BioAgilytix’s leadership team when the company was acquired in November 2019. She has also

held senior roles with Quintiles and Immucor.


Commenting on her new appointment, Dr. Robbie, said: “I could not be more enthusiastic to

step into this important role at BioAgilytix, as my predecessor leaves an incredible legacy of

high-performing teams and growth. This is an exciting time for me but also for BioAgilytix as we

chart our course forward.”


Dr. Robbie will continue to emphasize the importance of a strong science foundation and

leverage the global laboratory’s innovation skills while keeping focused on an exceptional

customer experience.


“Patient outcomes are always our first priority as we collaborate with our sponsors to deliver

accurate and reliable data for all of the studies that we support,” she shared.


Euan Menzies, CEO of BioAgilytix, added: “I am delighted to welcome such a high-calibre

appointment to our executive team. The skills that Linda brings to the table will be invaluable as

we continue to drive forward our strategy and move towards our next phase of growth.”


“Since joining BioAgilytix in mid-June, I have been consistently impressed with Linda’s

knowledge, expertise, and passion for delivering exceptional results. She has built a cohesive,

high-performing team in Boston, and I am confident she will have a similar positive impact

across the broader business.”


Dr. Robbie replaces Dr. Michael, who will be leaving the company at the end of the month.


“Linda inherits a strong foundation built by our prior COO, Dr. Steve Michael, and I would like to

thank Steve for his many contributions to BioAgilytix which have been key to our success,”

Menzies added.


About BioAgilytix

BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit